MacroGenics, Inc. (MGNX): Price and Financial Metrics

MacroGenics, Inc. (MGNX)

Today's Latest Price: $19.41 USD

0.46 (-2.32%)

Updated Oct 30 4:00pm

Add MGNX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

MGNX Stock Summary

  • Of note is the ratio of Macrogenics Inc's sales and general administrative expense to its total operating expenses; just 8.73% of US stocks have a lower such ratio.
  • With a price/sales ratio of 13.49, Macrogenics Inc has a higher such ratio than 89.52% of stocks in our set.
  • In terms of volatility of its share price, MGNX is more volatile than 91.95% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Macrogenics Inc, a group of peers worth examining would be MORF, VBLT, CARA, GRTS, and NTLA.
  • Visit MGNX's SEC page to see the company's official filings. To visit the company's web site, go to

MGNX Stock Price Chart Interactive Chart >

Price chart for MGNX

MGNX Price/Volume Stats

Current price $19.41 52-week high $32.18
Prev. close $19.87 52-week low $4.04
Day low $18.90 Volume 511,300
Day high $19.66 Avg. volume 1,337,448
50-day MA $25.51 Dividend yield N/A
200-day MA $19.01 Market Cap 1.05B

MacroGenics, Inc. (MGNX) Company Bio

Macrogenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The company was founded in 2000 and is based in Rockville, Maryland.

MGNX Latest News Stream

Event/Time News Detail
Loading, please wait...

MGNX Latest Social Stream

Loading social stream, please wait...

View Full MGNX Social Stream

Latest MGNX News From Around the Web

Below are the latest news stories about Macrogenics Inc that investors may wish to consider to help them evaluate MGNX as an investment opportunity.

MacroGenics' flotetuzumab shows positive effect in leukemia study

MacroGenics (MGNX) announces encouraging preliminary data from a Phase 1/2 clinical trial evaluating flotetuzumab in acute myeloid leukemia ((AML)) patients. The results were just published in the journal Blood.In a subset of patients high poor prognoses and high unmet medical needs, the complete remission rate was 16.7% (n=5/30) while the...

Seeking Alpha | September 22, 2020

MacroGenics MGD019 shows anti-tumor activity in advanced solid tumors

MacroGenics ([[MGNX]] -7.3%) announces clinical data from the dose escalation portion of a Phase 1 clinical trial of MGD019. The data were presented at the ESMO Virtual Congress 2020. MGD019, a bispecific PD-1 × CTLA-4 DART molecule, was designed to enhance CTLA-4 blockade on dual-expressing, tumor-infiltrating lymphocytes compared to a PD-1/CTLA-4...

Seeking Alpha | September 21, 2020

Is MacroGenics, Inc. (NASDAQ:MGNX) Trading At A 37% Discount?

In this article we are going to estimate the intrinsic value of MacroGenics, Inc. (NASDAQ:MGNX) by taking the expected...

Yahoo | July 31, 2020

MacroGenics Provides Update on Corporate Progress and Second Quarter 2020 Financial Results

Conference call scheduled for today at 4:30 p.m. ET.

GlobeNewswire | July 30, 2020

MacroGenics (MGNX) Reports Q2 Loss, Tops Revenue Estimates

MacroGenics (MGNX) delivered earnings and revenue surprises of -6.82% and 42.78%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | July 30, 2020

Read More 'MGNX' Stories Here

MGNX Price Returns

1-mo -24.59%
3-mo -23.58%
6-mo 171.47%
1-year 119.82%
3-year 0.36%
5-year -41.83%
YTD 78.40%
2019 -14.33%
2018 -33.16%
2017 -7.05%
2016 -34.00%
2015 -11.69%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7442 seconds.